Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2603618 plus gemcitabine versus gemcitabine in unresectable pancreatic cancer
NL-OMON36787Phase 2Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Oct 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in pancreatic adenocarcinoma (PDAC) comparing LY2603618 + gemcitabine with gemcitabine monotherapy (2 arms). Primary endpoints: Overall survival and Adverse events incidence. Started Oct 2011; status: active, not recruiting.
02
Drugs
rabusertibgemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NL-OMON36787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON36787.